HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?

Abstract

Authors

K Legg L Boland P Craddy G Foxon

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×